5 Best Immunology Stocks to Invest In

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 43  

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. On December 1, Regeneron Pharmaceuticals announced new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Immuno-Oncology Congress 2022 to be held in early December. 

On November 9, Truist analyst Robyn Karnauskas maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock and raised the price target to $856 from $790, highlighting that greater confidence in the stock reflects expectations that high-dose Eylea and its potential approval/launch in August 2023 may offer a longer tail.  

At the end of the third quarter of 2022, 43 hedge funds in the database of Insider Monkey held stakes worth $1.3 billion in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), compared to 44 in the preceding quarter worth $1.6 billion. 

In its Q3 2022 investor letter, Bronte Capital, an asset management firm, highlighted a few stocks and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was one of them. Here is what the fund said:

“There have been some bright spots in our long book. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a major position and a stock we wrote up in our June 2021 letter, has been one of the best-performing stocks in the S&P 500 this year. Alas, it has not been enough to offset some of our weaker stocks, let alone our overweight exposure to the UK (and Europe) which have suffered from both stock and currency weakness. We do not think we are bad at picking stocks on the long side and hope – reasonably we think – for better relative results in the future. Before COVID, our longs were markedly better than the index. Unfortunately, if you look at our long book this quarter and since the onset of the COVID pandemic, there is scant evidence that we have added any value by picking stocks to go long.”